nsc-95397 Search Results


nsc 95397  (TargetMol)
N/A
   Buy from Supplier
nsc 95397  (Santa Cruz Biotechnology)
90
Santa Cruz Biotechnology nsc 95397
Nsc 95397, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nsc-95397/NSC+95397/pmc04747493-47-10-12
Average 90 stars, based on 1 article reviews
nsc 95397 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
nsc95397  (MedChemExpress)
93
MedChemExpress nsc95397
PTX-induced <t>CtBP1</t> upregulation requires interaction with transcription partners to regulate ErbB2 transcription/expression in DRG neurons.. Diagram of the timeline of this experiment. Paclitaxel, PTX. Vehicle, VEH. DMSO, vehicle. NSC, <t>NSC95397,</t> CtBP1-protein partner interaction inhibitor.. (C) The paw mechanical threshold measured on day 14 in PTX or VEH rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 1, 10 and 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or VEH (vehicle). Each group: 6 rats. B, One-way ANOVA, F (5, 30) = 14.97, p < 0.0001. D, One-way ANOVA, F (2, 12) = 0.1286, p = 0.8805. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. The paw mechanical latency measured on day 14 in PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or VEH (vehicle). Each group: 6 rats. C, One-way ANOVA, F (3, 16) = 62.20, p < 0.0001.** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. Representative qPCR statistical analyses of ErbB2 mRNA abundances in the DRGs at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle). Relative quantification (RQ) = 2 −△△CT . Each group has 5 rats. One-way ANOVA, F (3, 16) = 19.32, p < 0.0001. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D. Representative Western blot and statistical analyses (normalized to GAPDH) of CtBP1 and ErbB2 abundances in the DRGs at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle). Each group has 5 rats. CtBP1, One-way ANOVA, F (3, 16) = 24.92, p < 0.0001. ErbB2, One-way ANOVA, F (3, 16) = 35.69, p < 0.0001.** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. ChIP-qPCR assay of the abundance of the CtBP1-precipitated ErbB2 promoter fragments at day at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle) Each group: 5 rats. CtBP1, One-way ANOVA, F (3, 16) = 33.00, p < 0.0001. IgG, One-way ANOVA, F (3, 16) = 0.17, p = 0.9140. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D
Nsc95397, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nsc-95397/NSC+95397/pmc12714790-105-15-27
Average 93 stars, based on 1 article reviews
nsc95397 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
nsc95397  (Enzo Biochem)
90
Enzo Biochem nsc95397
PTX-induced <t>CtBP1</t> upregulation requires interaction with transcription partners to regulate ErbB2 transcription/expression in DRG neurons.. Diagram of the timeline of this experiment. Paclitaxel, PTX. Vehicle, VEH. DMSO, vehicle. NSC, <t>NSC95397,</t> CtBP1-protein partner interaction inhibitor.. (C) The paw mechanical threshold measured on day 14 in PTX or VEH rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 1, 10 and 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or VEH (vehicle). Each group: 6 rats. B, One-way ANOVA, F (5, 30) = 14.97, p < 0.0001. D, One-way ANOVA, F (2, 12) = 0.1286, p = 0.8805. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. The paw mechanical latency measured on day 14 in PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or VEH (vehicle). Each group: 6 rats. C, One-way ANOVA, F (3, 16) = 62.20, p < 0.0001.** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. Representative qPCR statistical analyses of ErbB2 mRNA abundances in the DRGs at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle). Relative quantification (RQ) = 2 −△△CT . Each group has 5 rats. One-way ANOVA, F (3, 16) = 19.32, p < 0.0001. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D. Representative Western blot and statistical analyses (normalized to GAPDH) of CtBP1 and ErbB2 abundances in the DRGs at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle). Each group has 5 rats. CtBP1, One-way ANOVA, F (3, 16) = 24.92, p < 0.0001. ErbB2, One-way ANOVA, F (3, 16) = 35.69, p < 0.0001.** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. ChIP-qPCR assay of the abundance of the CtBP1-precipitated ErbB2 promoter fragments at day at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle) Each group: 5 rats. CtBP1, One-way ANOVA, F (3, 16) = 33.00, p < 0.0001. IgG, One-way ANOVA, F (3, 16) = 0.17, p = 0.9140. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D
Nsc95397, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nsc-95397/nsc95397/10__1091_slash_mbc__e10___07___0599-438-4-5
Average 90 stars, based on 1 article reviews
nsc95397 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
nsc 95397  (AUTODOCK GmbH)
90
AUTODOCK GmbH nsc 95397
PTX-induced <t>CtBP1</t> upregulation requires interaction with transcription partners to regulate ErbB2 transcription/expression in DRG neurons.. Diagram of the timeline of this experiment. Paclitaxel, PTX. Vehicle, VEH. DMSO, vehicle. NSC, <t>NSC95397,</t> CtBP1-protein partner interaction inhibitor.. (C) The paw mechanical threshold measured on day 14 in PTX or VEH rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 1, 10 and 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or VEH (vehicle). Each group: 6 rats. B, One-way ANOVA, F (5, 30) = 14.97, p < 0.0001. D, One-way ANOVA, F (2, 12) = 0.1286, p = 0.8805. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. The paw mechanical latency measured on day 14 in PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or VEH (vehicle). Each group: 6 rats. C, One-way ANOVA, F (3, 16) = 62.20, p < 0.0001.** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. Representative qPCR statistical analyses of ErbB2 mRNA abundances in the DRGs at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle). Relative quantification (RQ) = 2 −△△CT . Each group has 5 rats. One-way ANOVA, F (3, 16) = 19.32, p < 0.0001. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D. Representative Western blot and statistical analyses (normalized to GAPDH) of CtBP1 and ErbB2 abundances in the DRGs at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle). Each group has 5 rats. CtBP1, One-way ANOVA, F (3, 16) = 24.92, p < 0.0001. ErbB2, One-way ANOVA, F (3, 16) = 35.69, p < 0.0001.** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. ChIP-qPCR assay of the abundance of the CtBP1-precipitated ErbB2 promoter fragments at day at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle) Each group: 5 rats. CtBP1, One-way ANOVA, F (3, 16) = 33.00, p < 0.0001. IgG, One-way ANOVA, F (3, 16) = 0.17, p = 0.9140. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D
Nsc 95397, supplied by AUTODOCK GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nsc-95397/nsc+95397/pmc09031484-322-13-19
Average 90 stars, based on 1 article reviews
nsc 95397 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
cdc25 inhibitor cdc25 inhibitor ii  (Merck KGaA)
90
Merck KGaA cdc25 inhibitor cdc25 inhibitor ii
PTX-induced <t>CtBP1</t> upregulation requires interaction with transcription partners to regulate ErbB2 transcription/expression in DRG neurons.. Diagram of the timeline of this experiment. Paclitaxel, PTX. Vehicle, VEH. DMSO, vehicle. NSC, <t>NSC95397,</t> CtBP1-protein partner interaction inhibitor.. (C) The paw mechanical threshold measured on day 14 in PTX or VEH rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 1, 10 and 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or VEH (vehicle). Each group: 6 rats. B, One-way ANOVA, F (5, 30) = 14.97, p < 0.0001. D, One-way ANOVA, F (2, 12) = 0.1286, p = 0.8805. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. The paw mechanical latency measured on day 14 in PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or VEH (vehicle). Each group: 6 rats. C, One-way ANOVA, F (3, 16) = 62.20, p < 0.0001.** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. Representative qPCR statistical analyses of ErbB2 mRNA abundances in the DRGs at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle). Relative quantification (RQ) = 2 −△△CT . Each group has 5 rats. One-way ANOVA, F (3, 16) = 19.32, p < 0.0001. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D. Representative Western blot and statistical analyses (normalized to GAPDH) of CtBP1 and ErbB2 abundances in the DRGs at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle). Each group has 5 rats. CtBP1, One-way ANOVA, F (3, 16) = 24.92, p < 0.0001. ErbB2, One-way ANOVA, F (3, 16) = 35.69, p < 0.0001.** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. ChIP-qPCR assay of the abundance of the CtBP1-precipitated ErbB2 promoter fragments at day at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle) Each group: 5 rats. CtBP1, One-way ANOVA, F (3, 16) = 33.00, p < 0.0001. IgG, One-way ANOVA, F (3, 16) = 0.17, p = 0.9140. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D
Cdc25 Inhibitor Cdc25 Inhibitor Ii, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nsc-95397/cdc25+inhibitor+nsc+95397/pmc06192724-54-49-56
Average 90 stars, based on 1 article reviews
cdc25 inhibitor cdc25 inhibitor ii - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
erk pathways  (Selleck Chemicals)
91
Selleck Chemicals erk pathways
PTX-induced <t>CtBP1</t> upregulation requires interaction with transcription partners to regulate ErbB2 transcription/expression in DRG neurons.. Diagram of the timeline of this experiment. Paclitaxel, PTX. Vehicle, VEH. DMSO, vehicle. NSC, <t>NSC95397,</t> CtBP1-protein partner interaction inhibitor.. (C) The paw mechanical threshold measured on day 14 in PTX or VEH rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 1, 10 and 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or VEH (vehicle). Each group: 6 rats. B, One-way ANOVA, F (5, 30) = 14.97, p < 0.0001. D, One-way ANOVA, F (2, 12) = 0.1286, p = 0.8805. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. The paw mechanical latency measured on day 14 in PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or VEH (vehicle). Each group: 6 rats. C, One-way ANOVA, F (3, 16) = 62.20, p < 0.0001.** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. Representative qPCR statistical analyses of ErbB2 mRNA abundances in the DRGs at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle). Relative quantification (RQ) = 2 −△△CT . Each group has 5 rats. One-way ANOVA, F (3, 16) = 19.32, p < 0.0001. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D. Representative Western blot and statistical analyses (normalized to GAPDH) of CtBP1 and ErbB2 abundances in the DRGs at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle). Each group has 5 rats. CtBP1, One-way ANOVA, F (3, 16) = 24.92, p < 0.0001. ErbB2, One-way ANOVA, F (3, 16) = 35.69, p < 0.0001.** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. ChIP-qPCR assay of the abundance of the CtBP1-precipitated ErbB2 promoter fragments at day at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle) Each group: 5 rats. CtBP1, One-way ANOVA, F (3, 16) = 33.00, p < 0.0001. IgG, One-way ANOVA, F (3, 16) = 0.17, p = 0.9140. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D
Erk Pathways, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nsc-95397/NSC95397/pm35779282-56-5-11
Average 91 stars, based on 1 article reviews
erk pathways - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier
nsc 95397  (Enamine Ltd)
90
Enamine Ltd nsc 95397
PTX-induced <t>CtBP1</t> upregulation requires interaction with transcription partners to regulate ErbB2 transcription/expression in DRG neurons.. Diagram of the timeline of this experiment. Paclitaxel, PTX. Vehicle, VEH. DMSO, vehicle. NSC, <t>NSC95397,</t> CtBP1-protein partner interaction inhibitor.. (C) The paw mechanical threshold measured on day 14 in PTX or VEH rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 1, 10 and 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or VEH (vehicle). Each group: 6 rats. B, One-way ANOVA, F (5, 30) = 14.97, p < 0.0001. D, One-way ANOVA, F (2, 12) = 0.1286, p = 0.8805. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. The paw mechanical latency measured on day 14 in PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or VEH (vehicle). Each group: 6 rats. C, One-way ANOVA, F (3, 16) = 62.20, p < 0.0001.** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. Representative qPCR statistical analyses of ErbB2 mRNA abundances in the DRGs at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle). Relative quantification (RQ) = 2 −△△CT . Each group has 5 rats. One-way ANOVA, F (3, 16) = 19.32, p < 0.0001. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D. Representative Western blot and statistical analyses (normalized to GAPDH) of CtBP1 and ErbB2 abundances in the DRGs at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle). Each group has 5 rats. CtBP1, One-way ANOVA, F (3, 16) = 24.92, p < 0.0001. ErbB2, One-way ANOVA, F (3, 16) = 35.69, p < 0.0001.** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. ChIP-qPCR assay of the abundance of the CtBP1-precipitated ErbB2 promoter fragments at day at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle) Each group: 5 rats. CtBP1, One-way ANOVA, F (3, 16) = 33.00, p < 0.0001. IgG, One-way ANOVA, F (3, 16) = 0.17, p = 0.9140. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D
Nsc 95397, supplied by Enamine Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nsc-95397/NSC+95397/custom%40en300-18388556%4031281464
Average 90 stars, based on 1 article reviews
nsc 95397 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
nsc 95397  (Tocris)
N/A
Selective Cdc25 dual specificity phosphatase inhibitor
   Buy from Supplier
nsc 95397  (Aladdin Scientific Corporation)
N/A
product description：NSC 95397 is a potent, selective Cdc25 dual specificity phosphatase inhibitor with Ki of 32 nM, 96 nM, 40 nM for Cdc25A, Cdc25B and Cdc25C, respectively. NSC 95397 has IC50 of 22.3 nM, 56.9
   Buy from Supplier
nsc 95397  (BOC Sciences)
N/A
NSC 95397 is a 1,4-naphthoquinone-based irreversible inhibitor of Cdc25 dual-specificity phosphatases (Ki = 32, 96 and 40 nM for inhibition of Cdc25A, -B and -C respectively). NSC 95397 exhibits 125-180-fold selectivity over VH1-related dual-specificity phosphatase
   Buy from Supplier
nsc 95397  (Cayman Chemical)
N/A
NSC 95397
   Buy from Supplier

Image Search Results


PTX-induced CtBP1 upregulation requires interaction with transcription partners to regulate ErbB2 transcription/expression in DRG neurons.. Diagram of the timeline of this experiment. Paclitaxel, PTX. Vehicle, VEH. DMSO, vehicle. NSC, NSC95397, CtBP1-protein partner interaction inhibitor.. (C) The paw mechanical threshold measured on day 14 in PTX or VEH rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 1, 10 and 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or VEH (vehicle). Each group: 6 rats. B, One-way ANOVA, F (5, 30) = 14.97, p < 0.0001. D, One-way ANOVA, F (2, 12) = 0.1286, p = 0.8805. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. The paw mechanical latency measured on day 14 in PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or VEH (vehicle). Each group: 6 rats. C, One-way ANOVA, F (3, 16) = 62.20, p < 0.0001.** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. Representative qPCR statistical analyses of ErbB2 mRNA abundances in the DRGs at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle). Relative quantification (RQ) = 2 −△△CT . Each group has 5 rats. One-way ANOVA, F (3, 16) = 19.32, p < 0.0001. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D. Representative Western blot and statistical analyses (normalized to GAPDH) of CtBP1 and ErbB2 abundances in the DRGs at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle). Each group has 5 rats. CtBP1, One-way ANOVA, F (3, 16) = 24.92, p < 0.0001. ErbB2, One-way ANOVA, F (3, 16) = 35.69, p < 0.0001.** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. ChIP-qPCR assay of the abundance of the CtBP1-precipitated ErbB2 promoter fragments at day at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle) Each group: 5 rats. CtBP1, One-way ANOVA, F (3, 16) = 33.00, p < 0.0001. IgG, One-way ANOVA, F (3, 16) = 0.17, p = 0.9140. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D

Journal: Cell Biology and Toxicology

Article Title: CtBP1–LSD1 complex drives ErbB2 activation via H3K9me2 demethylation in DRGs during paclitaxel-induced neuropathic pain

doi: 10.1007/s10565-025-10122-7

Figure Lengend Snippet: PTX-induced CtBP1 upregulation requires interaction with transcription partners to regulate ErbB2 transcription/expression in DRG neurons.. Diagram of the timeline of this experiment. Paclitaxel, PTX. Vehicle, VEH. DMSO, vehicle. NSC, NSC95397, CtBP1-protein partner interaction inhibitor.. (C) The paw mechanical threshold measured on day 14 in PTX or VEH rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 1, 10 and 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or VEH (vehicle). Each group: 6 rats. B, One-way ANOVA, F (5, 30) = 14.97, p < 0.0001. D, One-way ANOVA, F (2, 12) = 0.1286, p = 0.8805. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. The paw mechanical latency measured on day 14 in PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or VEH (vehicle). Each group: 6 rats. C, One-way ANOVA, F (3, 16) = 62.20, p < 0.0001.** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. Representative qPCR statistical analyses of ErbB2 mRNA abundances in the DRGs at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle). Relative quantification (RQ) = 2 −△△CT . Each group has 5 rats. One-way ANOVA, F (3, 16) = 19.32, p < 0.0001. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D. Representative Western blot and statistical analyses (normalized to GAPDH) of CtBP1 and ErbB2 abundances in the DRGs at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle). Each group has 5 rats. CtBP1, One-way ANOVA, F (3, 16) = 24.92, p < 0.0001. ErbB2, One-way ANOVA, F (3, 16) = 35.69, p < 0.0001.** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D.. ChIP-qPCR assay of the abundance of the CtBP1-precipitated ErbB2 promoter fragments at day at day 14 of PTX rats in response to intrathecal injection NSC95397 (NSC; inhibit the CtBP1-protein partner interaction; 30 nM; 10 μL, administered twice daily for three consecutive days from day 11 to 13 after PTX treatment) or or VEH (vehicle) Each group: 5 rats. CtBP1, One-way ANOVA, F (3, 16) = 33.00, p < 0.0001. IgG, One-way ANOVA, F (3, 16) = 0.17, p = 0.9140. ** p < 0.01 vs. VEH 14D. ## p < 0.01 vs. PTX 14D

Article Snippet: AG825 (an ErbB2 inhibitor; 1, 30, and 100 nM; 10 μL; Tocris Bioscience, Bristol, UK), NSC95397 (a CtBP1 interaction blocker; 1, 10, and 30 nM; 10 μL; MedChemExpress, USA), and GSK-LSD1 (an LSD1 inhibitor; 1, 10, and 30 nM; 10 μL; Tocris Bioscience, Bristol, UK) were administered twice daily on days 11 to 13 following paclitaxel (PTX) treatment.

Techniques: Expressing, Injection, Quantitative Proteomics, Western Blot, ChIP-qPCR